FASENRA AstraZeneca Pty Ltd
Product name
FASENRA
Sponsor
Accepted date
Feb-2024
Active ingredients
benralizumab
Proposed indication
FASENRA is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.
Application type
C (new indication)
Publication date
Feb-2024